Generic Name and Formulations:
Losartan potassium, hydrochlorothiazide; 50mg/12.5mg, 100mg/12.5mg, 100mg/25mg; tabs.
Merck & Co., Inc.
Indications for HYZAAR:
Hypertension (not for initial therapy unless HTN is severe). To reduce stroke in hypertensive patients with left ventricular hypertrophy (LVH); this benefit may not apply to black patients.
≥18yrs: One 50/12.5mg tab once daily; may increase after about 3 weeks (2–4 weeks for severe HTN) to two 50/12.5mg tabs once daily or one 100/25mg tab once daily. Titrate components: see full labeling. HTN with LVH: switch from losartan monotherapy (see full labeling). Severe renal impairment (CrCl<30mL/min): not recommended.
<18yrs: not established.
Angiotensin II receptor blocker + thiazide diuretic.
Anuria. Sulfonamide allergy. Concomitant aliskiren in patients with diabetes.
Fetal toxicity may develop; discontinue if pregnancy is detected. Correct salt/volume depletion before starting therapy, or reduce initial dose. Renal impairment: monitor for worsening renal function. Hepatic impairment requiring titration with losartan: not recommended. Severe CHF. Renal artery stenosis. Asthma. SLE. Gout. Diabetes. Postsympathectomy. Acute myopia. Secondary angle-closure glaucoma. Pregnancy (Cat.D). Nursing mothers: not recommended.
See Contraindications. Hyperkalemia with K+ supplements, K+ sparing diuretics, K+ containing salt substitutes. Potentiated by fluconazole. Antagonized by rifampin. May be antagonized by, and renal toxicity potentiated by NSAIDs, including selective COX-2 inhibitors (monitor renal function periodically in elderly and/or volume-depleted). Dual inhibition of the renin-angiotensin system with ARBs, ACEIs, or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes; monitor closely. Avoid concomitant aliskiren in renal impairment (CrCl <60mL/min). Orthostatic hypotension with alcohol, other CNS depressants. Potentiates other antihypertensives, tubocurarine. Hypokalemia with corticosteroids, ACTH. May antagonize pressor amines (eg, norepinephrine), cholestyramine, colestipol resins. Adjust antihyperglycemics. May increase digitalis, lithium toxicity (monitor). May interfere with parathyroid tests.
Dizziness, abdominal pain, palpitations, back pain, sinusitis, cough, upper respiratory infection, rash, hyperkalemia; angioedema, syncope (discontinue if occurs), rhabdomyolysis (rare).
Hepatic (CYP2C9, 3A4).
Tabs—30, 90, 1000
Sign Up for Free e-newsletters
Cancer Therapy Advisor Articles
- Malignant Ascites: Diagnosis and Management
- Bipolar Androgen Therapy Showing Promise for Castration Resistant Prostate Cancer
- Pembrolizumab May Be More Effective, Safer Than Ipilimumab for Advanced Melanoma
- Doxorubicin More Effective Than Trabectedin for First-Line Sarcoma Treatment
- Alternate Sunitinib Schedules May Benefit Some with Metastatic Renal Cell Carcinoma
- Anti-PD-L1 Antibody Demonstrates Antitumor Activity in Triple-Negative Breast Cancer
- Milatuzumab Plus Veltuzumab Demonstrate Activity in B-Cell Non-Hodgkin Lymphoma
- Role of Genetic Mutations in Metastatic Castrate-Resistant Prostate Cancer Treatment
- Colorectal Cancer Screening in Older Adults Often Inappropriate
- After Breast Cancer, Many Women Express Desire for Genetic Testing
- Rociletinib Active in EGFR-Mutated Non-Small Cell Lung Cancer
- AZD9291 Highly Active in EGFR Inhibitor-Resistant Non-Small Cell Lung Cancer
- Small Response Rate in Cytarabine with Bolus for Acute Myeloid Leukemia
- Will Patient-Reported Outcomes Be Included in Oncology Product Labeling?
- Low Adherence in Cervical Cancer Screening Recommendations
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|